Research programme: transmembrane protein 175 agonists - AbbVie/Caraway Therapeutics
Alternative Names: TMEM175 activators - AbbVie/Caraway Therapeutics; TMEM175 agonists - AbbVie/Caraway TherapeuticsLatest Information Update: 16 Jan 2024
At a glance
- Originator Caraway Therapeutics
- Class Antiparkinsonians; Small molecules
- Mechanism of Action TMEM175 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Amyotrophic lateral sclerosis; Neurodegenerative disorders; Parkinson's disease
Most Recent Events
- 19 Sep 2023 Preclinical trials in Amyotrophic lateral sclerosis in USA (unspecified route) (Caraway Therapeutics pipeline, September 2023)
- 09 Jun 2021 Caraway Therapeutics and AbbVie enters a collaboration agreement for small molecule targeting TMEM175
- 09 Jun 2021 Preclinical trials in Neurodegenerative disorders in USA (unspecified route) before June 2021